For Research Purposes Only

PurePeptideHub
weight-lossclinical-trials

Retatrutide

Retatrutide (LY3437943)

Overview

A triple hormone receptor agonist (GLP-1/GIP/Glucagon) in clinical trials by Eli Lilly. Shows remarkable weight loss results up to 29% body weight. Often misleadingly called "GLP-3" on gray market.

Mechanism of Action

Activates three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon component may provide additional metabolic benefits and fat burning.

Popular Research Uses

  • Weight loss (investigational)
  • Metabolic health (investigational)

Potential Side Effects

  • Nausea (reported in trials)
  • Diarrhea
  • Vomiting
  • Constipation
  • Unknown - trials ongoing

Warnings

  • NOT FDA approved - still in clinical trials
  • Gray market versions are untested and potentially dangerous
  • "GLP-3" is a marketing term, not accurate
  • No established safety profile
  • Unknown long-term effects

Dosage Information

DO NOT use gray market versions. Wait for FDA approval and proper medical guidance.

Research Sources

Disclaimer: This content is for research and educational purposes only. Retatrutide is not approved for human consumption. Always consult with qualified healthcare professionals before making any decisions related to peptide research.